Christopher Ray Aker Regulus Therapeutics Inc. (RGLS) insider trading activity

Christopher Ray Aker is Sr. VP & General Counsel of Regulus Therapeutics Inc.. Currently has a direct ownership of 49,546 shares of RGLS, which is worth approximately $64,905. The most recent transaction as insider was on Jan 14, 2025, when has been sold 5,088 shares (Common Stock) at a price of $1.26 per share, resulting in proceeds of $6,410. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 49.5K

392.7% 3M change

392.7% 12M change

Total Value Held $64,905

Christopher Ray Aker Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
Jan 14 2025	SELL Open market or private sale	$6,410 $1.26 p/Share	5,088 Reduced 9.31%	49,546 Common Stock
Jan 13 2025	SELL Open market or private sale	$48,569 $1.26 p/Share	38,547 Reduced 41.37%	54,634 Common Stock
Jan 09 2025	BUY Grant, award, or other acquisition	$111,886 $1.33 p/Share	84,125 Added 47.45%	93,181 Common Stock
Jan 18 2024	SELL Open market or private sale	$6,506 $1.19 p/Share	5,468 Reduced 35.22%	10,056 Common Stock
Jan 12 2024	BUY Grant, award, or other acquisition	-	11,250 Added 42.02%	15,524 Common Stock
May 17 2021	SELL Open market or private sale	$765 $0.89 p/Share	860 Reduced 2.02%	41,754 Common Stock
Feb 16 2021	SELL Open market or private sale	$1,424 $1.72 p/Share	828 Reduced 1.91%	42,614 Common Stock
Nov 16 2020	SELL Open market or private sale	$456 $0.52 p/Share	876 Reduced 3.29%	25,762 Common Stock

CRA

Christopher Ray Aker

Sr. VP & General Counsel

San Diego, CA

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells RGLS shares.

Notify only if

Value

Insider Trading

Get notified when an Regulus Therapeutics Inc. insider buys or sells RGLS shares.

Notify only if

Operation

Value

Type

News

Receive news related to Regulus Therapeutics Inc.

Track Activities on RGLS

Account